Page last updated: 2024-08-26

mizoribine and Hypersensitivity, Type III

mizoribine has been researched along with Hypersensitivity, Type III in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akimoto, T; Ando, Y; Asano, Y; Ito, C; Kusano, E	1

Other Studies

1 other study(ies) available for mizoribine and Hypersensitivity, Type III

Article	Year
[Comparison of plasma exchange (PEX) vs. double filtration plasmapheresis (DFPP) with or without steroid administration in a case of MPO-ANCA-positive immune complex type crescentic glomerulonephritis]. Nihon Jinzo Gakkai shi, 2000, Volume: 42, Issue:5 Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Biomarkers; Combined Modality Therapy; Drug Therapy, Combination; Glomerulonephritis; Humans; Immune Complex Diseases; Immunosuppressive Agents; Male; Methylprednisolone; Peroxidase; Plasma; Plasma Exchange; Plasmapheresis; Prednisolone; Pulse Therapy, Drug; Ribonucleosides; Treatment Outcome	2000

Article

Year

[Comparison of plasma exchange (PEX) vs. double filtration plasmapheresis (DFPP) with or without steroid administration in a case of MPO-ANCA-positive immune complex type crescentic glomerulonephritis].

Nihon Jinzo Gakkai shi, 2000, Volume: 42, Issue:5

Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Biomarkers; Combined Modality Therapy; Drug Therapy, Combination; Glomerulonephritis; Humans; Immune Complex Diseases; Immunosuppressive Agents; Male; Methylprednisolone; Peroxidase; Plasma; Plasma Exchange; Plasmapheresis; Prednisolone; Pulse Therapy, Drug; Ribonucleosides; Treatment Outcome

2000